Merck Reports the CHMP’s Positive Opinions of Keytruda Regimens for Treating Indications of Gynecologic Cancers
Shots:
- The CHMP has granted positive opinions to Keytruda + carboplatin & paclitaxel followed by Keytruda alone as a 1L treatment of primary advanced/recurrent endometrial carcinoma and Keytruda + CRT for locally advanced cervical cancer (stage III-IVA) in treatment-naïve adults. The decision is anticipated in Q4’24
- The opinion in endometrial cancer was supported by the NRG-GY018 (KEYNOTE-868) study of the Keytruda regimen vs PBO, showing significantly improved PFS
- The recommendation in cervical cancer was based on the KEYNOTE-A18 (ENGOT-cx11/GOG-3047) study of Keytruda + CRT vs CRT alone, depicting significantly improved OS & PFS
Ref: Merck | Image: Merck
Related News:- Merck Reports the US FDA’s Approval of Keytruda Plus Pemetrexed and Platinum Chemotherapy to Treat Malignant Pleural Mesothelioma (MPM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
